Uflex Q1 FY27 Earnings Call — Analysis (NSE: UFLEX)
UFlex delivered record Q1FY27 EBITDA driven by overseas realization gains and supply-chain derisking, guiding for ~35% revenue and EBITDA growth in FY27 supported by new capacity ramp-ups.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Consolidated Revenue ₹5,397.20 Cr ( +38% YoY ) . New guidance — FY27 fy27 revenue and ebitda growth 35% . New story: Localized Sourcing Supply Derisking .
Results
Consolidated revenue grew 38% YoY to ₹5,397.20 Cr; reported EBITDA surged 92% YoY to ₹919.80 Cr (margin at 17.0%, +480bps YoY) and PAT expanded over 6x YoY to ₹423.30 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹5,397.20 Cr | +38% | yoy · Q1FY27 |
| Consolidated EBITDA | ₹919.80 Cr | +92% | yoy · Q1FY27 |
| Normalized EBITDA | ₹837.30 Cr | +78% | yoy · Q1FY27 · Adjusted for ₹82.50 Cr forex derivative gains |
| EBITDA Margin | 17.00% | +480bps | yoy · Q1FY27 |
| Normalized EBITDA Margin | 15.50% | none · Q1FY27 · Excluding forex derivatives | |
| Consolidated PAT | ₹423.30 Cr | +630% | yoy · Q1FY27 |
| PAT Margin | 7.80% | +630bps | yoy · Q1FY27 · vs 1.5% in Q1FY26 |
| Total Sales Volume | 173,471 MT | +1.7% | yoy · Q1FY27 |
| Packaging Films Volume | 136,186 MT | +4.9% | yoy · Q1FY27 |
| Packaging Volume | 37,285 MT | -8.4% | yoy · Q1FY27 |
| Capex Incurred | ₹478.20 Cr | none · Q1FY27 · Q1 capex across 4 main projects | |
| Debt to EBITDA Leverage | 3.5x | -1.0x | point_in_time · Q1FY27 · Jun-26 vs 4.5x in FY26 |
Guidance
Management guided for ~35% YoY growth in both revenue and EBITDA for FY27, with net debt-to-EBITDA expected to fall below 3x by FY28.
What management committed to
- [UFlex] expects 35% growth in top line and similarly 35% growth in EBITDA in FY27 compared to FY26. — 35%, FY27
- [UFlex] Greenfield Aseptic project in Egypt (12 billion packs) will be commercialized in H1 FY27. — 12 billion packs, Q2FY27
- [UFlex] Egypt Aseptic plant will utilize around 30% capacity (~2 billion packs) in FY27 post-commissioning. — ~2 billion packs / 30%, FY27
- [UFlex] leverage ratio will come down below 3x by end of FY28. — below 3x, FY28
- [UFlex] will reduce interest costs by at least 1% [100 bps] in the next 1 year. — 1%, Q1FY28
- [UFlex] will double its total production/sales volume in 3 years by FY29 relative to FY26. — double, FY29
- At least 60% to 70% of future capex allocation will go into value-added products. — 60% to 70%, going forward
- [UFlex] will invest USD 50+ million in Dharwad India Brownfield BOPP line across FY27 and FY28. — USD 50+ million, FY28
Key themes
Overseas margin surge and capacity commissioning
How the narrative shifted
- Localized Sourcing Supply Derisking: Global multi-location production network enables local supply to multinational converters, avoiding Red Sea/West Asia logistics disruptions and securing pricing premiums.
- Overseas Spreads and Realization Expansion: BOPET and BOPP price realizations have expanded 25-35% overseas with swift cost pass-throughs, driving 91% of incremental consolidated EBITDA.
- Value-Added Mix Transformation: Company is shifting capital and volumes away from commoditized packaging towards higher-margin Aseptic liquid packaging, WPP bags, and recycling.
- Capex Fruition and Deleveraging Cycle: With peak capex completing across Egypt, Mexico, and Noida, incremental operational cash flow will drive deleveraging to below 3x Debt/EBITDA by FY28.
- Domestic Import Competition vs FMCG Demand: Aseptic packaging in India faced short-term volume pressure from duty-free Indonesian imports, but domestic middle-class FMCG demand growth will absorb capacity.
Operational commentary
- Commissioned 39,600 MTPA recycling plant at Noida Sector 155 on April 30, 2026.
- Commissioned 80 million unit WPP bags facility in Mexico on July 31, 2026.
- 12 billion pack Greenfield Aseptic project in Egypt is on track for commercial commissioning in H1 FY27, undergoing active trials and approvals.
- BOPP realization is up 25-32% and BOPET realization is up 30-35% vs February 2026 levels, sustained by supply constraints and regional localized sourcing advantages amid West Asia crisis.
- Packaging volume softened 8.4% YoY due to strategic pruning towards higher-margin flexible packaging in India and duty-free import competition from Indonesia in aseptic packaging.
- Derisked global footprint enables self-sufficiency: Egypt and India PET chip plants supply resin directly to overseas film conversion lines in Mexico, Poland, Hungary, and Nigeria.
Analyst Q&A
Q. What magnitude of normalization in price realizations and margins should investors anticipate for Q2 FY27?
Management clarified that quarter-on-quarter fluctuations occur due to shipment timings and West Asia logistics, but year-on-year growth will remain strong with full-year FY27 targeting 35% revenue and profit growth.
Q. What is the capital allocation roadmap between capex, debt reduction, and shareholder distributions (buybacks/dividends)?
Surplus operating cash flow will prioritize growth capex (60-70% towards high-margin value-added verticals) and debt reduction to bring leverage below 3x by FY28; buybacks are considered unsuitable for high-growth phases.
Q. What revenue/profit CAGR should be modeled through FY29 as major capex reaches full utilization?
Management indicated an initial ballpark of ~10% CAGR from FY26 to FY29 top line but withheld exact model figures, stating IR will compute and confirm detailed numbers post-call.
Q. Why have diverse non-packaging items like paper, electronic devices, and infrastructure been added to the Articles of Association?
Management stated there is no immediate diversification outside packaging; amendments were enabling provisions for R&D and evolving substrate trends like paper packaging.
Research and educational content only. Not investment advice.